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ABSTRACT
Objective To evaluate apremilast treatment in patients
with active psoriatic arthritis, including current skin
involvement, despite prior therapy with conventional
disease-modifying antirheumatic drugs and/or biologic
agents.
Methods Patients (N=505) were randomised (1:1:1) to
placebo, apremilast 20 mg twice daily, or apremilast
30 mg twice daily. Rescue therapy with apremilast was
designated at week 16 for placebo patients not
achieving 20% improvement in swollen and tender joint
counts. At week 24, the remaining placebo
patients were then randomised to apremilast 20 mg
twice daily or 30 mg twice daily. The efﬁcacy and
safety of apremilast were assessed over 52 weeks.
Results At week 16, signiﬁcantly more patients
receiving apremilast 20 mg twice daily (28%) and 30 mg
twice daily (41%) achieved 20% improvement in
American College of Rheumatology response criteria
versus placebo (18%; p=0.0295 and p<0.0001,
respectively), and mean decrease in the Health
Assessment Questionnaire-Disability Index score was
signiﬁcantly greater with apremilast 30 mg twice daily
(−0.20) versus placebo (−0.07; p=0.0073). In patients
with baseline psoriasis body surface area involvement
≥3%, signiﬁcantly more apremilast 30 mg twice daily
patients achieved 50% reduction from baseline Psoriasis
Area and Severity Index score (41%) versus placebo
(24%; p=0.0098) at week 16. At week 52, observed
improvements in these measures demonstrated
sustained response with continued apremilast
treatment. Most adverse events were mild to moderate
in severity; the most common were diarrhoea, nausea,
headache and upper respiratory tract infection.
Conclusions Apremilast demonstrated clinically
meaningful improvements in psoriatic arthritis and
psoriasis at week 16; sustained improvements were seen
with continued treatment through 52 weeks. Apremilast
was generally well tolerated and demonstrated an
acceptable safety proﬁle.
Trial registration number NCT01212770.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic immune
disease. Manifestations of PsA include swollen and
tender joints, pain, and enthesitis and dacylitis,
which are associated with impaired physical func-
tion and health-related quality of life.1–4 There is
little evidence of effect for conventional disease-
modifying antirheumatic drugs (DMARDs), such as
methotrexate, in PsA treatment.5–9 When assessing
the effectiveness of a therapy for PsA, it is import-
ant to understand efﬁcacy in the context of active
skin disease and whether the therapy improves fea-
tures speciﬁcally associated with PsA.
Apremilast inhibits phosphodiesterase 4 (PDE4)
conversion of cyclic AMP to AMP, thus indirectly
downregulating the inﬂammatory response through
decreased inﬂammatory cytokine expression and
increased expression of anti-inﬂammatory cyto-
kines.10 The effect of apremilast on multiple mani-
festations of PsA is being assessed in patients with
active PsA in the Psoriatic Arthritis Long-term
Assessment of Clinical Efﬁcacy (PALACE) phase III
clinical trial programme. Previously reported results
of PALACE 1 have demonstrated the efﬁcacy of
apremilast in the treatment of PsA.11 12
PALACE 3 assessed apremilast treatment across
different aspects of PsA in patients with active
disease, including current skin disease. This report
describes the results of the ﬁrst 52 weeks of
PALACE 3.
METHODS
Patients
The study enrolled adults with PsA of ≥6 months’
duration who met the Classiﬁcation Criteria for
Psoriatic Arthritis (CASPAR) at screening and had
≥three swollen and ≥three tender joints. All
patients were required to have had prior treatment
with conventional DMARDs and/or biologics;
tumour necrosis factor inhibitor efﬁcacy failures
were limited to ≤10% of randomised patients.
Patients were also required to have active skin
disease with ≥one plaque psoriasis skin lesion
≥2 cm in size.
Patients were excluded if they had prior thera-
peutic failure of >three DMARDs or >one tumour
necrosis factor blocker; history of or current
rheumatic disease or autoimmune joint disease
other than PsA or functional class IV status as
deﬁned by the American College of Rheumatology
(ACR) Classiﬁcation of Functional Status in
Open Access
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Rheumatoid Arthritis; erythrodermic, guttate or generalised
pustular psoriasis; malignancy (except treated basal or squamous
cell skin carcinoma or early forms of cervical carcinoma with no
recurrence in 5 years); prior treatment with apremilast; or
phototherapy (ultraviolet B, psoralen+ultraviolet A) or
immunosuppressive systemic therapy (except as noted) within
4 weeks, adalimumab, etanercept, golimumab, inﬂiximab, certo-
lizumab pegol, or tocilizumab within 12 weeks, or alefacept or
ustekinumab within 24 weeks of randomisation. Patients with
active tuberculosis, history of incompletely treated tuberculosis
or signiﬁcant infection within 4 weeks of screening were
excluded. No puriﬁed protein derivative or QuantiFERON
screening for latent tuberculosis was required. There was no
protocol requirement to interrupt study medication for patients
who developed infection during the study, and no protocol pro-
hibition on vaccinations.
Patients taking concurrent DMARDs could continue stable
doses (≥4 weeks before baseline) of methotrexate (≤25 mg/
week), leﬂunomide (≤20 mg/day), sulfasalazine (≤2 g/day), or
combination. One DMARD dose reduction was allowed after
week 24. Stable doses of oral corticosteroids (prednisone
≤10 mg/day or equivalent for ≥4 weeks before baseline) and
non-steroidal anti-inﬂammatory drugs (for ≥2 weeks before
baseline) were permitted. Low potency topical corticosteroids
for treatment of face, axillae and groin psoriatic lesions, coal tar
shampoo and/or salicylic acid scalp preparations for scalp
lesions, and non-medicated emollient for body lesions were per-
mitted, except ≤24 h before study visits. The use of DMARDs
other than methotrexate, leﬂunomide or sulfasalazine was not
permitted ≤4 weeks of randomisation. Except for treatments
permitted as described above, topical therapy for psoriasis
≤2 weeks of randomisation was prohibited.
All patients provided written informed consent.
Study design
PALACE 3 is a phase III, randomised, placebo-controlled study
(see online supplementary ﬁgure S1). In the placebo-controlled,
double-blind phase, patients were randomised (1:1:1) to placebo,
apremilast 20 mg twice daily, or apremilast 30 mg twice daily
using a centralised interactive voice response system. Patients were
stratiﬁed by baseline DMARD use (yes/no) and psoriasis involve-
ment of the body surface area (BSA; <3%/≥3%). Apremilast was
dose-titrated over the 1st week of treatment (10 mg on day 1,
with increases of 10 mg/day until the target dose was reached).
Patients whose swollen joint count (SJC) and tender joint count
(TJC) had not improved by ≥20% at week 16 were considered
non-responders and were then randomised (1:1) to apremilast
20 mg twice daily or 30 mg twice daily if initially randomised to
placebo, or continued on their initial apremilast dose. At week
24, all remaining placebo patients were then randomised to apre-
milast 20 mg twice daily or 30 mg twice daily. Patients continued
in a 28-week double-blind, active treatment period up to week
52. A long-term extension phase is ongoing.
Efﬁcacy assessments
The primary efﬁcacy end point was the proportion of patients
achieving an ACR20 response at week 16 modiﬁed for PsA by
the addition of distal interphalangeal joints of the toes and the
carpometacarpal joints to TJC and SJC.13 14 The key secondary
end point was the change from baseline in the Health Assessment
Questionnaire-Disability Index (HAQ-DI) at week 16.15
Additional efﬁcacy measures included improvements in SJC and
TJC; physical function; enthesitis, measured by the presence or
absence of pain at 13 select entheses and tendon insertions16;
dactylitis, based on the number of digits on the hands and feet
with dactylitis present; and psoriasis activity, based on the pro-
portion of patients evaluable by the Psoriasis Area and Severity
Index (PASI) (baseline psoriasis involvement ≥3% BSA) who
achieved ≥75% or ≥50% reductions from baseline (PASI-75 or
PASI-50, respectively). Efﬁcacy end points were assessed at week
16, week 24 and week 52; ACR20 response, HAQ-DI scores,
and SJC and TJC were also evaluated at week 40.
Safety assessments
Safety assessments were conducted at screening, week 0, week
4, week 16, week 24, week 28, week 40 and week 52, and in
the event of early termination. Assessments included collection
of adverse events (AEs), clinical laboratory testing, physical
examinations, and vital signs at each visit, and 12-lead ECG at
screening and week 0, week 16, week 24 and week 52.
Statistical analysis
Sample size estimations were based on a phase II study of apre-
milast,17 which showed that a sample of 165 patients per group
would be needed to achieve 95% power to detect a 20% abso-
lute difference in the ACR20 response between apremilast treat-
ment and placebo using a two-group χ2 test at a two-sided
signiﬁcance level of 0.025.
Efﬁcacy at week 16 was evaluated for the intent-to-treat
population, which included all randomised patients who
received ≥one dose of study medication. Missing values were
handled using the non-responder imputation for categorical
variables and last-observation-carried-forward (LOCF) approach
for continuous variables. ACR20 response rates and other cat-
egorical variables at week 16 were compared using the
Cochran-Mantel-Haenszel test, controlling for baseline
DMARD use and baseline psoriasis (BSA <3%/≥3%). Changes
in HAQ-DI and other continuous variables from baseline to
week 16 were compared using an analysis of covariance
(ANCOVA) model with treatment, baseline DMARD use (yes/
no), and baseline psoriasis (BSA <3%/≥3) as factors and base-
line value as a covariate; per cent change from baseline was ana-
lysed based on the ANCOVA model using rank transformation.
For the assessment of changes in enthesitis and dactylitis
scores at week 24, values for all patients who qualiﬁed for early
escape at week 16 were deﬁned as missing at week 24 and
imputed using LOCF for the week 24 analysis.
Efﬁcacy analyses with no comparisons to placebo, including
those at week 52, were performed using the observed data for
each time point, which was the prespeciﬁed analysis at week 52.
Safety outcomes were assessed by study period and were ana-
lysed using the safety population, which comprised all patients
who received ≥one dose of study medication. Safety data were
analysed for two periods: the placebo-controlled period of week
0 to week 24 (data through week 16 for patients who initially
received placebo and escaped early; data through week 24 for all
other placebo patients and for patients randomised to apremilast)
and the 0-week to 52-week apremilast-exposure period (data are
included for all patients who received ≥one dose of apremilast,
regardless of when treatment started (week 0, week 16 or week
24)). AEs were classiﬁed using the Medical Dictionary for
Regulatory Activities classiﬁcation system. Events occurring after
the ﬁrst dose of study medication and ≤28 days after the last
dose were summarised descriptively.
RESULTS
Of 612 patients screened, 505 were randomised and received
≥one dose of study medication and were included in the
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intent-to-treat population (ﬁgure 1). Of these, 469 (93%) com-
pleted week 16, with comparable completion rates among apre-
milast and placebo groups (92–93%). Overall completion rates
for week 0–52 in apremilast 20 mg twice daily and 30 mg twice
daily patients were 71% (120/169) and 75% (126/167), respect-
ively. In addition, 72% (122/169) of patients randomised to
placebo at baseline completed week 52.
Randomised patients were representative of a population with
active PsA and were comparable across treatment arms for base-
line demographic and disease characteristics, as well as prior
and concurrent PsA-related therapy (table 1).
Efﬁcacy
At week 16, signiﬁcantly more apremilast 20 mg and 30 mg
patients achieved an ACR20 response versus placebo (placebo:
18%; 20 mg: 28%, p=0.0295; 30 mg: 41%, p<0.0001)
(ﬁgure 2A). The adjusted differences in response rate (95% CI)
versus placebo were 10% (1.1% to 18.6%) with apremilast
20 mg and 22% (13.0% to 31.6%) with 30 mg.
In subgroup analyses (prior or concomitant treatment) at
week 16, a consistent trend of higher ACR20 response rates in
either apremilast dose group versus the placebo group was
observed with and without concomitant conventional DMARD
use and regardless of prior biologic use or failure.
Biologic-naïve patients demonstrated numerically higher
responses (see online supplementary table S1).
Apremilast 30 mg was associated with a signiﬁcant improve-
ment in the HAQ-DI score versus placebo at week 16 (ﬁgure 2B).
Mean change from baseline in the HAQ-DI score at week 16 was
−0.20 with apremilast 30 mg versus −0.07 with placebo
(p=0.0073). Mean change in the HAQ-DI score with apremilast
20 mg (−0.13) did not reach statistical signiﬁcance versus
placebo. HAQ-DI improvement of ≥0.3018 was achieved by 31%
of patients receiving apremilast 20 mg, 32% receiving apremilast
30 mg and 24% receiving placebo; differences did not reach sig-
niﬁcance at week 16.
Signiﬁcantly more patients receiving apremilast 30 mg (41%;
p=0.0098) achieved PASI-50 (post hoc analysis) versus placebo
(24%) at week 16; PASI-50 achievement among patients receiv-
ing apremilast 20 mg (33%) was numerically higher but did not
reach statistical signiﬁcance (ﬁgure 2D). At week 16, signiﬁ-
cantly more apremilast 20 mg and 30 mg patients achieved
PASI-75 versus placebo (placebo: 8%; 30 mg: 21%, p=0.0098;
20 mg: 20%, p=0.0215) (table 2).
Apremilast 30 mg was associated with signiﬁcant results versus
placebo at week 16 in other prespeciﬁed end points, including
decreases in 28-joint disease activity score (DAS-28) and the
patient’s and physician’s global assessments of disease activity at
week 16. Signiﬁcant improvements in mean and mean per cent
change in TJC at week 16 were seen with both apremilast doses.
Signiﬁcant changes versus placebo at week 16 were not observed
with either dose of apremilast in proportions of patients attain-
ing ACR50 or ACR70, the mean change in C reactive protein
(CRP), and despite numerical trend, mean per cent change in
SJC; however, mean change in SJC was signiﬁcant for apremilast
30 mg versus placebo (−3.5 vs −1.3, p=0.01; table 2).
Figure 1 Patient disposition through week 52. *Includes withdrawal by patient, lost to follow-up, protocol violation, non-compliance, other.
†Includes patients initially randomised to placebo, who met early escape criteria and were then randomised to apremilast at week 16. ‡Includes
patients initially randomised to placebo who were then randomised to apremilast at week 24 for the active treatment phase (week 24–52). AE,
adverse event.
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Assessment of changes in enthesitis and dactylitis scores was
preplanned at week 24 as a pooled analysis for the PALACE
1, 2 and 3 programme. We present here the PALACE 3 results
at week 24. In patients with enthesitis at baseline, numerically
greater improvements in the Maastricht Ankylosing Spondylitis
Enthesitis Score (MASES) were seen, with mean changes of
−0.9 for apremilast 20 mg, −1.1 for apremilast 30 mg and −0.7
for placebo; results did not reach statistical signiﬁcance.
In patients with dactylitis at baseline, mean change in dactyli-
tis score at week 24 was signiﬁcantly improved for apremilast
30 mg (−2.4, p=0.0399 vs placebo). Results for apremilast
20 mg did not reach statistical signiﬁcance (−1.6) versus placebo
(−1.4).
Sustained therapeutic effect of apremilast was observed across
measures of efﬁcacy through week 52 in patients continuing
therapy (ﬁgure 3A–E and table 2).
Analysis of efﬁcacy with longer-term treatment suggested sus-
tained ACR20 response among patients initially randomised to
apremilast and completing 52 weeks of study treatment. At
week 52, 56% of patients receiving apremilast 20 mg and 63%
receiving apremilast 30 mg achieved an ACR20 response.
Sustained response rates were conﬁrmed using an LOCF analysis
Table 1 Baseline demographic and clinical characteristics: intent-to-treat population (N=505)*
Apremilast
Placebo
n=169
20 mg twice daily
n=169
30 mg twice daily
n=167
Age, mean (SD), years 49.5 (11.6) 49.6 (12.1) 49.9 (11.4)
Female, n (%) 91 (54) 90 (53) 88 (53)
Race, n (%)
White 158 (94) 161 (95) 163 (98)
Asian 7 (4) 6 (4) 2 (1)
Black 2 (1) 0 (0) 0 (0)
Other 2 (1) 2 (1) 2 (1)
Region, n (%)
North America 48 (28) 58 (34) 58 (35)
Europe 75 (44) 79 (47) 78 (47)
Rest of the world 46 (27) 32 (19) 31 (19)
Weight, mean (SD), kg 84.5 (20.0) 86.4 (20.1) 83.7 (20.1)
BMI, mean (SD), kg/m2 29.5 (6.4) 30.1 (6.3) 29.2 (6.4)
Duration, mean (SD), years
PsA 6.8 (6.5) 7.7 (7.7) 7.5 (7.6)
Psoriasis 17.8 (13.3) 18.3 (14.4) 17.1 (12.1)
Prior use of conventional DMARDs only (biologic-naïve), n (%) 121 (72) 118 (70) 124 (74)
Prior use of biologics, n (%) 48 (28) 50 (30) 43 (26)
Prior biologic therapeutic failures, n (%) 12 (7) 18 (11) 14 (8)
Baseline DMARD use, n (%) 101 (60) 104 (62) 101 (61)
MTX (mean dose: 14.75 mg/wk) 91 (54) 88 (52) 83 (50)
Leflunomide (mean dose: 19.20 mg/day) 5 (3) 12 (7) 8 (5)
Sulfasalazine (mean dose: 1.69 g/day) 10 (6) 10 (6) 14 (8)
Baseline corticosteroids† (mean dose: 6.52 mg/day), n (%) 16 (10) 34 (20) 23 (14)
SJC (0–76), mean (SD) 11.1 (7.9) 11.4 (9.1) 11.6 (8.7)
TJC (0–78), mean (SD) 18.3 (14.9) 20.8 (16.8) 20.9 (14.4)
HAQ-DI (0–3), mean (SD) 1.2 (0.63) 1.1 (0.65) 1.2 (0.67)
CRP (normal range: 0–0.5), mg/dL, mean (SD) 1.00 (1.35) 0.97 (1.51) 1.15 (1.88)
Patient’s global assessment of disease activity (0–100 mm VAS), mean (SD) 56.1 (21.0) 54.3 (20.9) 56.5 (24.2)
Physician’s global assessment of disease activity (0–100 mm VAS), mean (SD) 52.8 (18.8) 55.2 (18.8) 56.1 (18.2)
DAS-28 (CRP), mean (SD) 4.5 (1.1) 4.6 (1.1) 4.6 (1.0)
DAS-28 (CRP) <2.6, n (%) 6 (4) 4 (2) 1 (0.6)
BSA ≥3%, n (%)‡ 94 (56) 93 (55) 92 (55)
PASI score (0–72)‡, mean (SD) 7.6 (7.2) 7.6 (5.2) 7.9 (6.3)
Presence of enthesitis, n (%) 109 (65) 97 (57) 112 (67)
MASES (0–13), mean (SD) 4.4 (3.3) 4.4 (3.2) 4.4 (3.2)
Presence of dactylitis, n (%) 71 (42) 71 (42) 80 (48)
Dactylitis count (0–20), mean (SD) 3.9 (4.0) 3.7 (3.6) 4.1 (4.3)
*The n reflects the number of randomised patients; actual number of patients available for some parameters may vary slightly due to missing data.
†All converted to oral prednisone dose.
‡Examined among patients with BSA ≥3% at baseline and having data at baseline (placebo: n=86; apremilast 20 mg twice daily: n=87; apremilast 30 mg twice daily: n=89).
BMI, body mass index; BSA, body surface area; CRP, C reactive protein; DAS-28, 28-joint disease activity score; DMARDs, disease-modifying antirheumatic drugs; HAQ-DI, Health
Assessment Questionnaire-Disability Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis;
SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.
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at week 52 for any missing data; 52% of apremilast 30 mg
patients achieved an ACR20 response (see online supplementary
table S2). Similarly, changes in the HAQ-DI score and PASI-50
response in patients initially randomised to apremilast and com-
pleting 52 weeks of study treatment suggested sustained
improvement in physical function and skin involvement. Mean
changes in the HAQ-DI score were −0.33 (apremilast 20 mg)
and −0.35 (apremilast 30 mg). Similar observations were seen
with other secondary end points (table 2). Mean percentage
improvements in SJC of −62.6% for apremilast 20 mg and
−66.8% for apremilast 30 mg, as well as mean percentage
improvements in TJC of −53.8% (apremilast 20 mg) and
−53.5% (apremilast 30 mg) among patients treated for
52 weeks with apremilast indicates continued response to apre-
milast, as do mean changes in enthesitis (apremilast 20 mg:
−2.2; apremilast 30 mg: −1.9) and dactylitis (apremilast 20 mg:
−2.9; apremilast 30 mg: −3.6). Similarly, of patients who con-
tinued on apremilast 20 mg and 30 mg, 49% and 55% achieved
PASI-50 and 29% and 39% achieved PASI-75, respectively.
Treatment effects observed in patients initially randomised to
placebo and then randomised to apremilast at week 16 or week
24 were consistent with patients initially randomised to apremi-
last (table 2).
Safety
Table 3 provides an overview of AEs during the 24-week
placebo-controlled and 52-week apremilast-exposure phases.
During the placebo-controlled phase (week 0–24), the most
common AEs (≥5% of any treatment group) were diarrhoea,
nausea, headache and upper respiratory tract infection (table 3).
The majority of AEs were mild or moderate in severity.
Discontinuations due to AEs during the 24-week placebo-
controlled phase were ≤8% in any treatment group; few patients
who received apremilast from baseline (n=7) discontinued due
to AEs during week 24–52. Eighteen patients experienced a
serious AE (SAE) during the placebo-controlled phase and 23
experienced an SAE during the 52-week apremilast-exposure
phase. All SAEs during the apremilast-exposure phase were
reported in one patient per treatment group, except worsening
of PsA, which was reported in two apremilast 20 mg patients
(table 3). No major adverse cardiac events occurred during the
placebo-controlled or apremilast-exposure phases. Two malig-
nancies (one breast cancer, one small cell lung cancer) were
detected during the placebo-controlled period (both with apre-
milast 20 mg) and were not considered treatment related.
In the apremilast treatment groups, diarrhoea and nausea
occurred at the highest frequency during the ﬁrst 2 weeks of
dosing, and decreased thereafter. Most AEs of diarrhoea and
nausea were mild to moderate in severity and resolved within
30 days of onset with continued therapy and without medicinal
intervention. In patients receiving apremilast from baseline and
remaining on apremilast ≤52 weeks, new reports of diarrhoea
and nausea were uncommon between week 24 and week 52 for
apremilast 20 mg (diarrhoea: n=3/170; nausea: n=3/170) and
30 mg (diarrhoea: n=2/167; nausea: n=5/167). No SAEs of
diarrhoea or nausea were reported throughout the 52-week
apremilast-exposure phase. Overall, <2% of patients receiving
apremilast discontinued because of diarrhoea or nausea through
52 weeks.
Marked abnormalities in vital signs, haematology and clinical
chemistry variables were infrequent and occurred at a similar
frequency with placebo or apremilast (table 3). Weight decrease
was reported as an AE in a small proportion of patients during
the 24-week placebo-controlled phase as well as during the
52-week apremilast-exposure phase. By week 24, mean change
in weight from baseline to the last value measured was −0.05 kg
(placebo), −1.2 kg (20 mg) and −1.2 kg (30 mg). Most patients
Figure 2 ACR20 (A), HAQ-DI (B), SJC and TJC (C) and PASI-50 (D) at
week 16. *p<0.05; †p≤0.0001 versus placebo, based on analysis of
covariance model for HAQ-DI, SJC and TJC, and Cochran-Mantel-
Haenszel test for ACR20 and PASI-50 for the intent-to-treat population;
patients who discontinued or did not have sufﬁcient data were counted
as non-responders (ACR20 and PASI-50) or had their last observation
was carried forward (HAQ-DI, SJC and TJC). Error bars represent SE.
ACR, American College of Rheumatology; BSA, body surface area;
HAQ-DI, Health Assessment Questionnaire-Disability Index; PASI-50,
50% reduction from baseline Psoriasis Area and Severity Index; SJC,
swollen joint count; TJC, tender joint count.
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maintained their weight ≤5% of baseline; at the end of the
52-week apremilast-exposure phase, weight loss >5% was
observed in 14% (34/237) of apremilast 20 mg patients and
16% (38/237) of 30 mg patients.
Around 60% of participants were taking conventional
DMARDs at the start of the trial (50% methotrexate with a
mean dose of 14.75 mg/week). Common AEs were generally
similar regardless of concomitant conventional DMARD use
(see online supplementary table S3); no additional safety signals
were observed.
DISCUSSION
PsA is a chronic disorder that frequently requires long-term
treatment. Because the pathophysiological mechanisms leading
to psoriasis and PsA are closely tied, and most patients with PsA
have coexistent psoriasis, it is important that agents used to
treat PsA also demonstrate efﬁcacy in improving psoriasis skin
lesions. Patients enrolled in PALACE 3 had active PsA as well as
active skin disease. This study demonstrated a signiﬁcant thera-
peutic effect of apremilast 20 mg twice daily and 30 mg twice
daily on disease activity, including improvement in signs and
symptoms of PsA as well as psoriasis in a population with broad
prior treatment experience.
Apremilast demonstrated clinically meaningful improvements
in PsA disease severity at week 16, marked by signiﬁcantly
greater achievement of ACR20 response in both apremilast dose
groups (vs placebo) as well as improvements in physical function
based on the HAQ-DI (apremilast 30 mg), mean and mean per
cent change in TJC, mean change in SJC (apremilast 30 mg),
mean change in DAS-28 (CRP), patients achieving DAS-28
(CRP) <2.6, and physician’s and patient’s global assessments of
disease activity (apremilast 30 mg); mean change in dactylitis
count was signiﬁcantly greater with apremilast 30 mg than with
placebo at week 24. Despite numerical trends in some, ACR50/
ACR70 responses, achievement of HAQ-DI minimal clinically
important difference ≥0.30, change in CRP and mean per cent
change in SJC were not signiﬁcant at week 16. Similarly, week
24 changes in MASES were numerically greater with apremilast
30 mg, but not signiﬁcant. A trend of higher ACR20 response
rates with either apremilast dose (vs placebo), regardless of prior
biologic exposure (biologic-naïve, biologic-experienced and bio-
logic therapeutic failures) was seen, but responses were numeric-
ally lower for the biologic-experienced patients.
Table 2 Efficacy end points at week 16 (intent-to-treat population) and week 52 (data as observed)
Week 16 (intent-to-treat population) Week 52 (data as observed)
Placebo
n=169
Apremilast
20 mg twice
daily
n=169
Apremilast
30 mg twice
daily
n=167
Placebo/
apremilast
20 mg twice daily
n=55
Placebo/
apremilast
30 mg twice daily
n=67
Apremilast
20 mg twice
daily
n=120
Apremilast
30 mg twice
daily
n=126
ACR20, n/m (%)* 31/169 (18) 48/169 (28)§ 68/167 (41)|| 32/54 (59) 39/67 (58) 65/116 (56) 80/127 (63)
ACR50, n/m (%)* 14/169 (8) 21/169 (12) 25/167 (15) 15/53 (28) 21/66 (32) 30/119 (25) 38/126 (30)
ACR70, n/m (%)* 4/169 (2) 8/169 (5) 6/167 (4) 11/53 (21) 10/67 (15) 11/120 (9) 13/125 (10)
ACR response components
HAQ-DI (0–3), mean change (SD) −0.07 (0.41) −0.13 (0.45) −0.20 (0.46)§ −0.34 (0.41) −0.34 (0.49) −0.33 (0.51) −0.35 (0.51)
HAQ-DI MCID ≥0.30†, n/m (%)* 40/169 (24) 52/169 (31) 54/167 (32) 31/55 (56) 37/67 (55) 55/122 (45) 66/127 (52)
CRP (normal range:
0–0.5), mg/dL, mean change (SD)
−0.02 (1.25) −0.23 (1.24) −0.11 (1.78) −0.02 (1.06) −0.28 (1.17) −0.23 (1.56) −0.33 (1.68)
SJC (0–76), mean change (SD) −1.3 (7.0) −2.3 (8.6) −3.5 (8.1)§ −7.3 (6.0) −7.1 (8.0) −7.5 (9.5) −7.8 (7.8)
SJC (0–76), mean per cent change (SD) −9.6 (72.5) −21.9 (72.4) −24.5 (95.8) −66.6 (38.6) −69.1 (41.6) −62.6 (44.3) −66.8 (49.2)
TJC (0–78), mean change (SD) −0.8 (8.9) −4.0 (10.3)§ −6.3 (10.5)|| −8.4 (14.6) −8.9 (8.9) −11.0 (14.1) −10.7 (11.5)
TJC (0–78), mean per cent change (SD) 0.9 (67.8) −24.8 (51.8)|| −32.1 (55.5)|| −46.4 (71.9) −58.7 (45.1) −53.8 (46.2) −53.5 (47.6)
Patient’s global assessment of disease
activity (0–100 mm VAS), mean change (SD)
−4.1 (26.1) −5.2 (30.3) −9.7 (28.9)§ −21.1 (23.4) −15.3 (30.5) −11.4 (27.4) −17.9 (29.1)
Physician’s global assessment of disease
activity (0–100 mm VAS), mean change (SD)
−7.4 (21.1) −13.9 (24.0)§ −20.0 (22.3)|| −29.8 (23.3) −28.2 (20.4) −30.4 (22.9) −31.5 (21.0)
DAS-28 (CRP), mean change (SD) −0.28 (1.0) −0.57 (1.2)§ −0.77 (1.1)|| −1.3 (1.1) −1.3 (1.2) −1.2 (1.1) −1.4 (1.2)
DAS-28 (CRP) <2.6,
n/m (%)*
13/169 (8) 29/169 (17)§ 30/167 (18)§ 18/54 (33) 26/67 (39) 34/121 (28) 38/127 (30)
PASI-50, n/m (%)*‡ 21/89 (24) 30/91 (33) 37/90 (41)§ 16/24 (67) 19/35 (54) 31/63 (49) 35/64 (55)
PASI-75, n/m (%)*‡ 7/89 (8) 18/91 (20)§ 19/90 (21)§ 8/24 (33) 10/35 (29) 18/63 (29) 25/64 (39)
Note: For week 16 data, the n reflects the number of randomised patients; actual number of patients available for continuous parameters may vary slightly due to missing value at
baseline or missing postbaseline value at or before week 16. For week 52 data, placebo/apremilast 20 mg twice daily and placebo/apremilast 30 mg twice daily groups include patients
who were randomised to placebo at baseline and then randomised to apremilast 20 mg twice daily or 30 mg twice daily, respectively, at week 16 and week 24. Apremilast 20 mg twice
daily and 30 mg twice daily groups include patients randomised to the respective regimen at baseline; data as observed. The n reflects the number of randomised patients who completed
52 weeks; actual number of patients may vary for each end point depending on availability of data.
*Patients who discontinued or did not have sufficient data at week 16 were counted as non-responders.
†Prespecified MCID threshold, based on the literature18 at the time of protocol development and analysis planning.
‡At week 16, examined among patients with body surface area ≥3% at baseline (placebo: n=89; apremilast 20 mg twice daily: n=91; apremilast 30 mg twice daily: n=90); at week 52,
examined among patients with body surface area ≥3% at baseline and having data at week 52 (placebo/apremilast 20 mg twice daily: n=24; placebo/apremilast 30 mg twice daily: n=35;
apremilast 20 mg twice daily: n=63; apremilast 30 mg twice daily: n=64).
§p<0.05; ||p≤0.0001 versus placebo, based on ANCOVA model for continuous end points and Cochran-Mantel-Haenszel test for categorical end points.
ACR, American College of Rheumatology; ANCOVA; analysis of covariance; CRP, C reactive protein; DAS-28, 28-joint disease activity score; HAQ-DI, Health Assessment
Questionnaire-Disability Index; MCID, minimal clinically important difference; PASI-75, 75% reduction from baseline Psoriasis Area and Severity Index score; SJC, swollen joint count; TJC,
tender joint count; VAS, visual analogue scale.
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Psoriasis severity was signiﬁcantly decreased at week 16
among patients with psoriasis BSA involvement of ≥3% at
baseline. Although the study inclusion criteria mandated active
skin disease in all patients, those evaluable by PASI constituted
about 55% of the population enrolled, with PASI scores
slightly lower than in PALACE 1.11 Efﬁcacy data in patients
with more severe psoriasis are available from the Efﬁcacy and
Safety Trial Evaluating the Effects of Apremilast in Psoriasis
(ESTEEM) studies.19 20 PASI responses in PsA are often not
as robust as responses shown in psoriasis studies. Psoriasis
involvement of <10% of BSA at baseline or baseline PASI
scores <10 have been associated with poorer PASI
responsiveness than that seen for patients with greater psoria-
sis involvement.21 22
Improvements in one or both apremilast dose groups (vs
placebo) at week 16 in secondary end points, including
health-related quality of life and measures of global PsA disease
activity, demonstrated the shorter-term effect of apremilast
across the manifestations of PsA. In patients remaining on apre-
milast therapy for ≤52 weeks, observed improvements from
baseline across many of these measures suggest sustained
response.
The observed safety proﬁle was similar to that in previous
apremilast investigations and consistent over the 24-week and
Figure 3 Over 52 weeks, ACR20 (A), HAQ-DI (B), PASI-50 (C), SJC (D) and TJC (E) (data as observed). Error bars represent SE. ACR, American
College of Rheumatology; BSA, body surface area; HAQ-DI, Health Assessment Questionnaire-Disability Index; n/m=number of responders/number of
patients with sufﬁcient data for evaluation; PASI-50, 50% reduction from baseline Psoriasis Area and Severity Index score; SJC, swollen joint count;
TJC, tender joint count.
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52-week phases. The most common AEs, diarrhoea and nausea,
occurred most often during the ﬁrst 2 weeks of apremilast treat-
ment, with a reduced incidence after the 1st month of dosing,
and were generally mild or moderate in severity. Laboratory
abnormalities were infrequent and did not indicate a need for
laboratory monitoring.
Efﬁcacy and safety assessments during the active treatment
phase describe the effects of apremilast observed among patients
who continued its use over 52 weeks. The 52-week continuation
rate in PALACE 3 was 73%, which is within the same range as
the continuation rates observed in studies of biologics in patients
with PsA.23–25 Long-term assessments may be biased based on
the likelihood that patients not responding to or tolerating treat-
ment may be more likely to discontinue. It is notable, however,
that, over 52 weeks, <10% of patients discontinued apremilast
because of AEs, and <10% discontinued because of lack of efﬁ-
cacy. A limitation of the PALACE study design includes the lack
of radiographic assessment; further studies are needed to fully
evaluate the effect of apremilast on joint damage progression.
The short length of the placebo-controlled part of the study is
also a limitation, as a meaningful analysis of safety is not pos-
sible in the context of a brief placebo-controlled phase (data
through week 16 for patients who initially received placebo and
escaped early; data through week 24 for all other patients).
Whereas a lengthier placebo-controlled phase would provide
more rigorous comparative data, it also presents ethical
limitations; the week 24–52 active treatment period provided an
alternative means to describe tolerability and safety of apremilast
among those patients with longer-term exposure. Results from
open-label extensions of the PALACE programme up to an add-
itional 4 years will provide more information on the long-term
use of apremilast.
These ﬁndings are important, as a need remains for long-term
treatment options for patients with PsA, including those with
active psoriasis skin lesions. Based on the signiﬁcant efﬁcacy
seen with apremilast 30 mg in PALACE 3 in several domains of
PsA, including ACR20 response, changes in HAQ-DI, mean and
mean per cent change in TJC, mean change in SJC, dactylitis
count, and DAS-28 (CRP), achievement of DAS-28 (CRP) <2.6,
physician’s and patient’s global assessments of disease activity,
and skin involvement, as well as a favourable risk:beneﬁt proﬁle
and apparent lack of need for ongoing laboratory monitoring,
apremilast represents a new oral treatment option, with a
unique mode of action, for patients with PsA.
Correction notice This article has been corrected since it was published Online
First. At the end of the ﬁrst paragraph of the Methods/Patients section >2 cm has
been corrected to ≥2 cm.
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Table 3 AEs and laboratory abnormalities during the placebo-controlled phase (week 0–24) and apremilast-exposure phase (week 0–52)
Week 0–24* Week 0–52†
Apremilast Apremilast
Placebo
n=168
20 mg twice
daily
n=170
30 mg twice
daily
n=167
20 mg twice
daily
n=241
30 mg twice
daily
n=242
Overview of AEs, n (%)
Any AE 83 (49) 100 (59) 104 (62) 160 (66) 165 (68)
Any serious AE 9 (5) 3 (2) 6 (4) 13 (5) 10 (4)
Any AE leading to drug withdrawal 10 (6) 13 (8) 12 (7) 22 (9) 14 (6)
Death 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
AEs reported by ≥5% of patients in any treatment group, n (%)
Diarrhoea 3 (2) 26 (15) 26 (16) 32 (13) 33 (14)
Nausea 9 (5) 19 (11) 23 (14) 24 (10) 36 (15)
Headache 8 (5) 16 (9) 20 (12) 26 (11) 26 (11)
URTI 3 (2) 11 (7) 12 (7) 21 (9) 20 (8)
Nasopharyngitis 2 (1) 7 (4) 4 (2) 12 (5) 10 (4)
Vomiting 1 (0.6) 5 (3) 8 (5) 8 (3) 12 (5)
Serious AEs reported by ≥2 patients in any treatment group, n (%)
Acute pancreatitis 2 (1) 0 (0) 0 (0) 0 (0) 0 (0)
Psoriatic arthropathy 2 (1) 1 (0.6) 1 (0.6) 2 (0.8) 1 (0.4)
Select laboratory assessments, n/m‡ (%)
ALT >150 U/L 0/167 (0) 0/168 (0) 2/164 (1) 2/238 (0.8) 2/238 (0.8)
Creatine (male >156, female >126 μmol/L) 1/167 (0.6) 0/168 (0) 0/164 (0) 1/238 (0.4) 0/238 (0)
Haemoglobin (male: decrease >2.0 and value <10.5 g/dL; female:
decrease >2.0 and value <10.0 g/dL)
0/165 (0) 1/162 (0.6) 0/161 (0) 1/232 (0.4) 3/236 (1)
Leucocytes <2.0, 109/L 0/165 (0) 0/162 (0) 1/161 (0.6) 0/238 (0) 2/238 (0.8)
Neutrophils <0.75, 109/L 1/164 (0.6) 1/161 (0.6) 0/161 (0) 1/238 (0.4) 0/238 (0)
Platelets <75, 109/L 0/165 (0) 0/162 (0) 0/161 (0) 0/238 (0) 0/238 (0)
*Placebo-controlled phase includes data through week 16 for patients initially receiving placebo who escaped, and data through week 24 for all other patients.
†Includes all patients who received ≥1 dose of apremilast regardless of when apremilast was started (week 0, week 16 or week 24).
‡Represents patients with ≥1 occurrence of the abnormality (n)/patients with a baseline value and ≥1 postbaseline value for criteria requiring baseline or patients with ≥1 postbaseline
value for criteria not requiring baseline (m). Individual abnormalities were infrequent and returned to baseline values with continuation of apremilast administration or were associated
with a concurrent medical condition or medication.
AEs, adverse events; ALT, alanine aminotransferase; URTI, upper respiratory tract infection.
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